Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Tumor Microenvironment02:17

The Tumor Microenvironment

7.9K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.0K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K
Tumor Progression02:07

Tumor Progression

7.5K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.5K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

6.1K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
6.1K
Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

6.1K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
6.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Interaction of molecular nitrogen with vanadium oxide in the absence and presence of water vapor at room temperature: Near-ambient pressure XPS.

The Journal of chemical physics·2022
Same author

Functionalised peptide hydrogel for the delivery of cardiac progenitor cells.

Materials science & engineering. C, Materials for biological applications·2020
Same author

Design-augmented (DA) biologics: BMP chimeras for bone and cartilage regeneration.

Osteoarthritis and cartilage·2019
Same author

DHPS-dependent hypusination of eIF5A1/2 is necessary for TGFβ/fibronectin-induced breast cancer metastasis and associates with prognostically unfavorable genomic alterations in TP53.

Biochemical and biophysical research communications·2019
Same author

Carborane-based polymers: a novel class of semiconductors with tunable properties.

Physical chemistry chemical physics : PCCP·2017
Same author

CRIPTO and its signaling partner GRP78 drive the metastatic phenotype in human osteotropic prostate cancer.

Oncogene·2017

Related Experiment Video

Updated: Feb 14, 2026

Microfluidic Device for Recreating a Tumor Microenvironment in Vitro
16:18

Microfluidic Device for Recreating a Tumor Microenvironment in Vitro

Published on: November 20, 2011

12.1K

Tumor microenvironment heterogeneity: challenges and opportunities.

F Runa1, S Hamalian1, K Meade1

  • 1Department of Biology, California State University, Northridge, CA.

Current Molecular Biology Reports
|February 13, 2018
PubMed
Summary

The tumor microenvironment (TME) is crucial in breast and prostate cancers, influencing disease progression and treatment outcomes. Understanding its complex cellular makeup offers new therapeutic strategies for these malignancies.

Keywords:
Cancer Associated FibroblastsCancer Progression/RecurrenceEMTExtracellular matrix (ECM)Mesenchymal Stem Cells (MSCs)MetastasisSignaling PathwaysTherapy ResistancesTumor Associated Macrophages (TAMs)Tumor Microenvironment (TME)

More Related Videos

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
07:54

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on: October 25, 2011

19.2K
Enrichment and Characterization of the Tumor Immune and Non-immune Microenvironments in Established Subcutaneous Murine Tumors
08:32

Enrichment and Characterization of the Tumor Immune and Non-immune Microenvironments in Established Subcutaneous Murine Tumors

Published on: June 7, 2018

10.5K

Related Experiment Videos

Last Updated: Feb 14, 2026

Microfluidic Device for Recreating a Tumor Microenvironment in Vitro
16:18

Microfluidic Device for Recreating a Tumor Microenvironment in Vitro

Published on: November 20, 2011

12.1K
Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
07:54

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on: October 25, 2011

19.2K
Enrichment and Characterization of the Tumor Immune and Non-immune Microenvironments in Established Subcutaneous Murine Tumors
08:32

Enrichment and Characterization of the Tumor Immune and Non-immune Microenvironments in Established Subcutaneous Murine Tumors

Published on: June 7, 2018

10.5K

Area of Science:

  • Oncology
  • Cancer Biology
  • Immunology

Background:

  • The tumor microenvironment (TME) is a key factor in breast and prostate cancer progression.
  • It comprises immune cells, fibroblasts, endothelial cells, mesenchymal stem cells (MSCs), and extracellular matrix (ECM).
  • The TME significantly impacts tumor growth, metastasis, and treatment resistance.

Purpose of the Study:

  • To discuss the molecular and cellular heterogeneity within the tumor microenvironment.
  • To explore the challenges and opportunities presented by TME complexity in cancer treatment.
  • To highlight the role of the TME in breast and prostate cancers.

Main Methods:

  • Review of current literature on tumor microenvironment components.
  • Analysis of molecular and cellular characteristics of the TME.
  • Discussion of therapeutic implications based on TME heterogeneity.

Main Results:

  • The TME exhibits significant molecular and cellular diversity in breast and prostate cancers.
  • This heterogeneity complicates standard treatment approaches.
  • Specific TME components offer potential targets for novel therapies.

Conclusions:

  • Targeting the complex TME is essential for improving breast and prostate cancer treatment.
  • Further research into TME composition can lead to personalized therapeutic strategies.
  • Understanding TME heterogeneity is critical for overcoming therapeutic resistance and recurrence.